-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Biogen, Lowers Price Target to $169

Benzinga·05/07/2025 13:16:42
Listen to the news
Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $207 to $169.